Evidence-Based Medicine for Student Health Services
Robert J. Flaherty, MD
Swingle Student Health Service
Montana State University
Bozeman, MT 59717
 
Sinusitis 
  
Etiology Monitoring
Epidemiology Prognosis
Diagnosis Prevention
Treatment Patient Education
  
General Information
    
EBM for Student Health   
     Home Page   
    
About EBM   
   
EBM Resources  
  
Specific Conditions/Diseases 
 
   
     
 
   
Etiology  
No evidence is cited.  
   
Epidemiology  
No evidence is cited.  
   
Diagnosis  
Clinical Diagnosis 
Five clinical findings 
  • Maxillary toothache
  • Poor response to decongestants
  • A history of colored nasal discharge
  • Purulent nasal secretion
  • Transillumination result (useful only if negative)
are the best predictors of acute bacterial sinusitis (level I evidence). When <2 of these findings was present sinusitis could be ruled out; however, when >3 are present, the likelihood of sinusitis  is very high. When 2 or 3 findings are present a Waters view may be useful (level III evidence). 
  • Caveats
    • Age group studied: Unknown
    • Type/size: Hierarchical evaluation of the strength of evidence in the medical literature and consensus of experts. Emphasis was placed on randomized, placebo-controlled clinical trials (level I evidence) and well-designed controlled trials without randomization (level II evidence) when available. Opinions of respected authorities based on clinical experience, descriptive studies and reports of expert committees (level III evidence) were assigned a lower weight. 
    • Population characteristics: Unknown
    • Outcome measures: Unknown
  • Citations
The following signs and symptoms increase the likelihood of bacterial sinusitis:   
  • "Double-sickening" (an upper respiratory infection that initially improves then worsens)
  • Purulent secretions by history 
  • Purulent secretions in the nasal cavity on examination 
  • Lack of response to decongestants and antihistamines 
  • Unilateral maxillary pain
Facial pain on percussion or palpation, sedimentation rate and white blood count have little diagnostic value.     
Laboratory/X-ray Diagnosis 
Regarding the following five clinical findings:  
  • Maxillary toothache
  • Poor response to decongestants
  • A history of colored nasal discharge
  • Purulent nasal secretion
  • Transillumination result (useful only if negative)
Radiography is not warranted when <2  or >3 of these findings are present. When 4 or more are present, the likelihood of sinusitis is very high. A Waters view is useful when the diagnosis is in doubt (level III evidence). CT scans are not cost-effective and should not be used routinely to diagnose acute sinusitis (level II evidence). 
  • Caveats
    • Age group studied: Unknown
    • Type/size: Hierarchical evaluation of the strength of evidence in the medical literature and consensus of experts. Emphasis was placed on randomized, placebo-controlled clinical trials (level I evidence) and well-designed controlled trials without randomization (level II evidence) when available. Opinions of respected authorities based on clinical experience, descriptive studies and reports of expert committees (level III evidence) were assigned a lower weight. 
    • Population characteristics: Unknown
    • Outcome measure: Unknown
  • Citations
    
Treatment   
Antibiotics 
No specific antibiotic is likely to be helpful in most cases of acute maxillary sinusitis. It may be more appropriate to prescribe antibiotics only for patients who are sicker, or at higher risk for complications. When antibiotics are used, clinicians should choose the cheapest and most convenient agent available. Optimal duration of therapy remains controversial.  In the event that antibiotics are used, first-line therapy should be a 10-day course of amoxicillin or trimethoprim­ sulfamethoxazole (level I evidence) and a decongestant (level III evidence). Patients not responding to first-line therapy should be switched to a second-line agent (any agent with an approved indication for acute bacterial sinusitis other than amoxicillin and TMP­SMX). As well, patients with recurrent episodes of acute sinusitis who have been assessed and found not to have anatomic anomalies may also benefit from second-line therapy (level III evidence).   
  • Caveats
    • Age group studied: Unknown
    • Type/size: Hierarchical evaluation of the strength of evidence in the medical literature and consensus of experts. Emphasis was placed on randomized, placebo-controlled clinical trials (level I evidence) and well-designed controlled trials without randomization (level II evidence) when available. Opinions of respected authorities based on clinical experience, descriptive studies and reports of expert committees (level III evidence) were assigned a lower weight. 
    • Population characteristics: Unknown
    • Outcome measure: Unknown
  • Citations
In the event that antibiotics are used, three days of trimethoprim/sulfasoxazole (TMP/SMX) is as effective as 10 days of TMP/SMX in the treatment of acute maxillary sinusitis (77% and 76% cured or much improved at 14 days).   Cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten were compared to conventional antibiotic therapies (usually amoxicillin/clavulanate, cefaclor or cephalexin) for community acquired infections. Infections included acute otitis media, pharyngitis, sinusitis, bronchitis, pneumonia, urinary tract infection and skin and skin-structure infections. The newer agents appear to be as clinically effective as conventional therapies (but not more effective) for the treatment of common community-acquired infections. They may also have the potential to improve compliance due to their once/twice daily mode of 
administration.  
  • Caveats
    • Age group studied: Unknown
    • Type/size: Analytical review of studies: acute otitis media: 19 studies, pharyngitis: 13 studies, sinusitis: 4 studies, bronchitis: 10 studies, pneumonia: 7 studies, urinary tract infection: 11 studies, skin and skin-structure infections: 4 studies. Most studies consisted of 30-50 patients in each arm
    • Population: Unknown
    • Outcome measure: Clinical response to therapy
    • For some of these infections other studies show that there is no evidence that any antibiotic therapy is beneficial
  • Citations
Amoxicillin and trimethoprim/sulfasoxazole are essentially as effective as more expensive antibiotics for the initial treatment of uncomplicated acute sinusitis.   Receiving a prescription for an antibiotic for a URI was not associated with increased patient satisfaction. Better to spend time explaining the nature of a particular illness and the physician's choice of treatment.  Other Therapies    
  • Decongestants, along with antimicrobial therapy, are useful in treating acute sinusitis (level III evidence). 
  • Antihistamines are contraindicated in the management of acute sinusitis (level III evidence). 
  • Glucocorticosteroids have not been shown to be of any notable benefit in treating acute sinusitis (level III evidence). 
  • Irrigation of the nasal cavity may provide symptomatic relief (level III evidence).  
  • Caveats
    • Age group studied: Unknown
    • Type/size: Hierarchical evaluation of the strength of evidence in the medical literature and consensus of experts. Emphasis was placed on randomized, placebo-controlled clinical trials (level I evidence) and well-designed controlled trials without randomization (level II evidence) when available. Opinions of respected authorities based on clinical experience, descriptive studies and reports of expert committees (level III evidence) were assigned a lower weight. 
    • Population characteristics: Unknown
    • Outcome measure: Unknown
  • Citations
  
Monitoring 
No evidence is cited. 
  
Prognosis   
No evidence is cited.   
   
Prevention  
No evidence is cited.   
  
Patient Education 
The following patient education materials are consistent with the available evidence. 
Rev. 8/28/99
   
 [Return to Top of Page]  
  
This Web site developed and maintained by Robert J. Flaherty, MD. 
Comments, additions and corrections are encouraged.